

PROSTATE CANCER PROGRAM OVERVIEW

MSK's urologic cancer program is recognized as one of the world's finest,



ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.

We provide patients with:

- safer and more precise treatments
- the benefit of seeing several dedicated prostate cancer specialists on one day, at one location
- an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
- access to innovative clinical trials of therapies, surgical and radiation therapy techniques, and advanced technologies not available at other hospitals
- genomic sequencing for all patients to look for actionable mutations

LOCATIONS

Many of our specialists are centrally located at our **Manhattan location**. We also have regional outpatient locations in:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, New York

REFER A PATIENT

Contact the Physician Access Service directly at

800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

Our Team Leaders

James A. Eastham, MD, FACS
Chief, Urology Service; Peter T. Scardino Chair in Oncology

Howard I. Scher, MD
Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; D. Wayne Calloway Chair in Urologic Oncology

Michael J. Zelefsky, MD
Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service

Peter T. Scardino, MD, FACS
David H. Koch Chair

Philip Kantoff, MD
Chair, Department of Medicine; George J. Bosl Chair

Vincent P. Laudone, MD
Chief of Surgery, Josie Robertson Surgery Center

Victor E. Reuter, MD
Vice Chair, Department of Pathology; Director, Genitourinary Pathology; Director, Genitourinary Pathology Fellowship; Director, Pathology Core Facility

Brett S. Carver, MD
Surgeon

Behfar Ehdai, MD, MPH
Surgeon

Sign up for OncoNotes, MSK's clinical updates newsletter.

Go to MSKCC.org, click on the **For Health Professionals** section, and choose "Sign Up for Our E-newsletter."



Memorial Sloan Kettering
Cancer Center



Prostate Cancer Program




Memorial Sloan Kettering
Cancer Center

WHY CHOOSE MSK FOR PROSTATE CANCER CARE?



By the Numbers



Leadership

- We provide one of the largest prostate cancer programs in the country, performing **more than 800 surgeries per year** for new cancers, including patients who are not considered to be surgical candidates elsewhere.
- MSK founded and coordinates the **Prostate Cancer Clinical Trials Consortium**, a 13-member, multi-institutional research organization collaborating on over 140 clinical trials seeking to translate new drug discoveries to improved standards of care.
- MSK leads the **National Cancer Institute's Specialized Program of Research Excellence (SPORE) for prostate cancer**, focused on defining the mechanisms of disease, developing validated assays and biomarkers for clinical trials, and demonstrating better outcomes for patients.
- **We have over 47 prostate cancer clinical trials underway** for a range of targeted therapies, immunotherapies, and novel surgical approaches.

Expertise

- MSK prostate cancer experts have led **all the drug discoveries** that underpin clinical advances in prostate cancer treatment. Our expertise gives us an edge anticipating side effects, response rates, and drug resistance at the earliest stages.
- Our researchers developed the **4Kscore test that identifies men with an elevated PSA score who have a low risk of harboring a high-grade prostate cancer**, enabling them to safely postpone or avoid a biopsy.
- Whether employing robotic or open radical prostatectomy, our surgeons operate with precision to **preserve erectile tissue and continence**.

Advanced Technologies

- We pioneered **stereotactic hypofractionated accelerated radiation to the prostate, or SHARP**, to safely and effectively deliver powerful doses of radiation directly to a person's tumor with incredible precision.
- For most patients, we use the latest robotic surgical techniques, resulting in **lower blood loss, decreased postoperative pain, shorter hospital stays, and faster recovery** times than open surgery.
- We routinely utilize **MSK-IMPACT™**, a genome sequencing test developed at MSK, that quickly determines if tumors have actionable mutations using available targeted therapies or if patients may benefit from clinical trials.
- Our researchers are evaluating **liquid biopsies** that may better characterize prostate cancer and response to treatment. We are working with the FDA to incorporate liquid biopsies as biomarkers in clinical trials.